Cannabinoid receptor type 2 agonist JWH-133 deteriorates the liver toxicity induced by cypermethrin

Cannabinoid receptor 2 (CB2) has a role in the pathology of some liver diseases. Cypermethrin (CYP) is a synthetic pyrethroid insecticide used commonly for the control of pests and vectors, and for protection of foodstuffs. In this study, the involvement of CB2 in CYP-induced liver damage in rats was investigated. CYP was applied to rats orally at a dose of 125 mg/kg bw per day for 14 days. CB2 agonist JWH-133 was administered by intraperitoneal injection at a dose of 3 mg/kg bw per day for the last 4 days of CYP toxicity. JWH-133 deteriorated the liver damage induced by CYP. JWH-133 increased serum hepatic enzyme activities (aspartate aminotransferase, alanine aminotransferase) in rats given CYP. However, it decreased lipid peroxidation. There were no differences in the levels of hepatic CB2 mRNA among the groups. CB2 receptors were expressed in a small amount in normal liver tissue. In contrast, the expression levels of CB2 in CYP-treated rats were increased in fibrocyte/fibroblast, bile duct epithelial cells, Kupffer cells, and mast cells. In conclusion, CB2 was upregulated in the liver exposed to CYP, predominantly in hepatic fibrogenic cells. JWH-133 enhanced the CYP-induced liver damage by receptor mediated and/or nonreceptor-mediated mechanisms. CB2 antagonists may reduce the damage. The results of the study show that CB2 might be involved in the physiopathological process of CYP-induced liver injury and justify the need for further study.

Keywords:

Cannabinoid receptor type 2, CB2, cypermethrin, JWH-133 liver, rat,

PDF

___

Nair RR, Abraham MJ, Nair N, Lalithakunjamma C, Aravindakshan C. Hematological and biochemical profile in sub lethal toxicity of cypermethrin in rats. International Journal of Biological and Medical Research 2010; 1: 211-214.
Kanbur M, Eraslan G, Ince S, Altintas L, Liman BC, Bayram L. The effects of propetamphos, cypermethrin and propetamphos- cypermethrin combination on some biochemical and histopathological parameters in mice. Kafkas Üniversitesi Veteriner Fakültesi Dergisi 2015; 21: 187-194.
Kumar Singh A, Nath Tiwari M, Prakash O, Pratap Singh M. A current review of cypermethrin-induced neurotoxicity and nigrostriatal dopaminergic neurodegeneration. Curr Neuropharmacol 2012; 10: 64-71.
Suvetha L, Ramesh M, Saravanan M. Influence of cypermethrin toxicity on ionic regulation and gill Na+/K+-ATPase activity of a freshwater teleost fish Cyprinus carpio . Environ Toxicol Phar 2010; 29: 44-49.
Aldana L, Tsutsumi V, Craigmill A, Silveira MI, de Mejia EG. α-Tocopherol modulates liver toxicity of the pyrethroid cypermethrin. Toxicol Lett 2001; 125: 107-116.
Yavasoglu A, Sayim F, Uyanikgil Y, Turgut M, Karabay- Yavasoglu NÜ. The pyrethroid cypermethrin-induced biochemical and histological alterations in rat liver. J Health Sci 2006; 52: 774-780.
Abdou HM, Hussien HM, Yousef MI. Deleterious effects of cypermethrin on rat liver and kidney: protective role of sesame oil. J Environ Sci Heal B 2012; 47: 306-314.
Manna S, Bhattacharyya D, Mandal TK, Das S. Sub-chronic toxicity study of alfa-cypermethrin in rats. Iranian Journal of Pharmacology and Therapeutics 2006; 5: 163-166.
Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990; 346: 561-564.
Munro S, Thomas KL, Abu-Shaar M. Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993; 365: 61-65.
Pacher P, Bátkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58: 389-462.
Parfieniuk A, Flisiak R. Role of cannabinoids in chronic liver diseases. World J Gastroentero 2008; 14: 6109-6114.
Pacher P, Hasko G. Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning. Brit J Pharmacol 2008; 153: 252-262.
Pacher P, Gao B. Endocannabinoids and liver disease. III. Endocannabinoid effects on immune cells: implications for inflammatory liver diseases. Am J Physiol-Gastr L 2008; 294: 850-854.
Izzo AA, Camilleri M. Emerging role of cannabinoids in gastrointestinal and liver diseases: basic and clinical aspects. Gut 2008; 57: 1140-1155.
Mallat A, Teixeira-Clerc F, Deveaux V, Lotersztajn S. Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases. Expert Opin Ther Tar 2007; 11: 403-409.
Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med 1967; 70: 158-169.
Sun E, Xu H, Liu Q, Zhou J, Zuo P, Wang J. The mechanism for the effect of selenium supplementation on immunity. Biol Trace Elem Res 1995; 48: 231-238.
Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Chem 1979; 95: 351-358.
Chatterjee S, Gangula PR, Dong Y, Yallampalli C. Immunocytochemical localization of nitric oxide synthase-III in reproductive organs of female rats during the oestrous cycle. Histochem J 1996; 28: 715-723.
Beltramo M, Bernardini N, Bertorelli R, Campanella M, Nicolussi E, Fredduzzi S, Reggiani A. CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 2006; 23: 1530-1538.
Felder CC, Veluz JS, Williams HL, Briley EM, Matsuda LA. Cannabinoid agonists stimulate both receptor-and non- receptor-mediated signal transduction pathways in cells transfected with and expressing cannabinoid receptor clones. Mol Pharmacol 1992; 42: 838-845.
Quistad GB, Sparks SE, Casida JE. Fatty acid amide hydrolase inhibition by neurotoxic organophosphorus pesticides. Toxicol Appl Pharm 2001; 173: 48-55.
Nallapaneni A, Liu J, Karanth S, Pope C. Modulation of paraoxon toxicity by the cannabinoid receptor agonist WIN 55,212-2. Toxicology 2006; 227: 173-183.
Slipetz DM, O’Neill GP, Favreau L, Dufresne C, Gallant M, Gareau Y, Guay D, Labelle M, Metters KM. Activation of the human peripheral cannabinoid receptor results in inhibition of adenylyl cyclase. Mol Pharmacol 1995; 48: 352-361.
Sugiura T, Kondo S, Kishimoto S, Miyashita T, Nakane S, Kodaka T, Suhara Y, Takayama H, Waku K. Evidence that 2-arachidonoylglycerol but not N -palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J Biol Chem 2000; 275: 605-612.
Islam MS, Hoque MM, Ferdousi Z. Cypermethrin-induced changes in body morphometrics and histopathology of liver and kidneys in the Swiss Albino Mice Mus Musculus L. Journal of Global Biosciences 2014; 3: 1004-1015.
Nair RR, Abraham MJ, Lalithakunjamma C, Nair ND, Aravindakshan CM. A pathomorphological study of the sublethal toxicity of cypermethrin in Sprague Dawley rats. International Journal of Nutrition, Pharmacology, Neurological Diseases 2011; 1: 179-183.
Husain K, Scott BR, Reddy SK, Somani SM. Chronic ethanol and nicotine interaction on rat tissue antioxidant defense system. Alcohol 2001; 25: 89-97. 30. Eraslan G, Kanbur M, Silig Y, Karabacak M, Soyer Sarlca Z, Sahin S. The acute and chronic toxic effect of cypermethrin, propetamphos, and their combinations in rats. Environ Toxicol 2015; 31: 1415-1429.
Yousef MI, Awad TI, Mohamed EH. Deltamethrin-induced oxidative damage and biochemical alterations in rat and its attenuation by Vitamin E. Toxicology 2006; 227: 240-247.
Bátkai S, Osei-Hyiaman D, Pan H, El-Assal O, Rajesh M, Mukhopadhyay P, Hong F, Harvey-White J, Jafri A, Hasko G et al. Cannabinoid-2 receptor mediates protection against hepatic ischemia/reperfusion injury. FASEB J 2007; 21: 1788-1800.
Rajesh M, Pan H, Mukhopadhyay P, Bátkai S, Osei-Hyiaman D, Haskó G, Liaudet L, Gao B, Pacher P. Pivotal advance: cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis. J Leukocyte Biol 2007; 82: 1382-1389.
Muthuviveganandavel V, Muthuraman P, Muthu S, Srikumar K. A study on low dose cypermethrin induced histopathology, lipid peroxidation and marker enzyme changes in male rat. Pestic Biochem Phys 2008; 91: 12-16.
Desco MC, Asensi M, Márquez R, Martinez-Valls J, Vento M, Pallardó FV, Sastre J, Vina J. Xanthine oxidase is involved in free radical production in type 1 diabetes. Diabetes 2002; 51: 1118-1124.
Matsumoto S, Koshiishi I, Inoguchi T, Nawata H, Utsumi H. Confirmation of superoxide generation via xanthine oxidase in streptozotocin-induced diabetic mice. Free Radical Res 2003; 37: 767-772.
Montecucco F, Lenglet S, Braunersreuther V, Burger F, Pelli G, Bertolotto M, Mach F, Steffens S. CB2 cannabinoid receptor activation is cardioprotective in a mouse model of ischemia/ reperfusion. J Mol Cell Cardiol 2009; 46: 612-620.
Zaidi SKR, Banu N. Antioxidant potential of vitamins A, E and C in modulating oxidative stress in rat brain. Clin Chim Acta 2004; 340: 229-233.
Hübner-Woniak E, Lutoslawska G, Panczenko-Kresowska B, Sitkowski D. The effect of oxygen uptake at anaerobic threshold on resting plasma concentrations of reduced glutathione and thiobarbituric acid reactive substances (TBARS), and on the antioxidant enzyme activities in blood. Biol Sport 2005; 22: 151-161.
Kostka T, Drai J, Berthouze S, Lacour JR, Bonnefoy M. Physical activity, fitness and integrated antioxidant system in healthy active elderly women. Int J Sports Med 1998; 19: 462-467.
Avraham Y, Zolotarev O, Grigoriadis NC, Pautahidis T, Magen I, Vorobiav L, Zimmer A, Ilan Y, Mechoulam R, Berry EM. Cannabinoids and capsaicin improve liver function following thioacetamide-induced acute injury in mice. Am J Gastroenterol 2008; 103: 3047-3056.
Teixeira-Clerc F, Belot MP, Manin S, Deveaux V, Cadoudal T, Chobert MN, Louvet A, Zimmer A, Tordmann T, Mallat A et al. Beneficial paracrine effects of cannabinoid receptor 2 on liver injury and regeneration. Hepatology 2010; 52: 1046-1059.
Julien B, Grenard P, Teixeira-Clerc F, Van Nhieu JT, Li L, Karsak M, Zimmer A, Mallat A, Lotersztajn S. Antifibrogenic role of the cannabinoid receptor CB2 in the liver. Gastroenterology 2005; 128: 742-755.
Mendez-Sanchez N, Zamora-Valdes D, Pichardo-Bahena R, Barredo-Prieto B, Ponciano-Rodriguez G, Bermejo-Mart 횤 nez L. Endocannabinoid receptor CB2 in nonalcoholic fatty liver disease. Liver Int 2007; 27: 215-219.
Muñoz-Luque J, Ros J, Fernández-Varo G, Tugues S, Morales- Ruiz M, Alvarez CE, Friedman SL, Arroyo V, Jimenez W. Regression of fibrosis after chronic stimulation of cannabinoid CB2 receptor in cirrhotic rats. J Pharmacol Exp Ther 2008; 324: 475-483.
Lichtinghagen R, Musholt PB, Lein M, Römer A, Rudolph B, Kristiansen G, Hauptmann S, Schnorr D, Loening SA, Jung K. Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. Eur Urol 2002; 42: 398-406.
Sarro SM, Unruh TL, Zuccolo J, Sanyal R, Luider JM, Auer- Grzesiak IA, Mansoor A, Deans JP. Quantification of CD20 mRNA and protein levels in chronic lymphocytic leukemia suggests a post-transcriptional defect. Leukemia Res 2010; 34: 1670-1673.
Tian Q, Stepaniants SB, Mao M, Weng L, Feetham MC, Doyle MJ, Yi EC, Dai H, Thorsson V, Eng J et al. Integrated genomic and proteomic analyses of gene expression in mammalian cells. Mol Cell Proteomics 2004; 3: 960-969.
Schwanhäusser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chem W, Selbach M. Corrigendum: global quantification of mammalian gene expression control. Nature 2013; 495: 126- 127.
Schwanhäusser B, Busse D, Li N, Dittmar G, Schuchhardt J, Wolf J, Chen W, Selbach M. Global quantification of mammalian gene expression control. Nature 2011; 473: 337- 342.
Auguet T, Berlanga A, Guiu-Jurado E, Terra X, Martinez S, Aguilar C, Filiu E, Alibalic A, Sabench F, Hernandez M et al. Endocannabinoid receptors gene expression in morbidly obese women with nonalcoholic fatty liver disease. Biomed Res Int 2014; 2014: 1-8.
Deveaux V, Cadoudal T, Ichigotani Y, Teixeira-Clerc F, Louvet A, Manin S, Tran-Van Nhieu J, Belot MP, Zimmer A, Even P et al. Cannabinoid CB2 receptor potentiates obesity-associated inflammation, insulin resistance and hepatic steatosis. PLoS One 2009; 4: e5844.
Koda W, Harada K, Tsuneyama K, Kono N, Sasaki M, Matsui O, Nakanuma Y. Evidence of the participation of peribiliary mast cells in regulation of the peribiliary vascular plexus along the intrahepatic biliary tree. Lab Invest 2000; 80: 1007-1017.
Matsunaga Y, Terada T. Mast cell subpopulations in chronic inflammatory hepatobiliary diseases. Liver 2000; 20: 152-156.
Zweifel M, Breu K, Matozan K, Renner E, Welle M, Schaffner T, Clavien PA. Restoration of hepatic mast cells and expression of a different mast cell protease phenotype in regenerating rat liver after 70%-hepatectomy. Immunol Cell Biol 2005; 83: 587- 595.
Facci L, Dal Toso R, Romanello S, Buriani A, Skaper S, Leon A. Mast cells express a peripheral cannabinoid receptor with differential sensitivity to anandamide and palmitoylethanolamide. P Natl Acad Sci USA 1995; 92: 3376- 3380.
Samson MT, Small-Howard A, Shimoda LM, Koblan- Huberson M, Stokes AJ, Turner H. Differential roles of CB1 and CB2 cannabinoid receptors in mast cells. J Immunol 2003; 170: 4953-4962.
Shibamoto T, Tsutsumi M, Kuda Y, Ohmukai C, Zhang W, Kurata Y. Mast cells are not involved in the ischemia- reperfusion injury in perfused rat liver. J Surg Res 2012; 174: 114-119.
Yang M, Ma Y, Tao S, Ding J, Rao L, Jiang H, Li JY. Mast cell degranulation promotes ischemia-reperfusion injury in rat liver. J Surg Res 2014; 186: 170-178.
Jonsson KO, Persson E, Fowler CJ. The cannabinoid CB 2 receptor selective agonist JWH133 reduces mast cell oedema in response to compound 48/80 in vivo but not the release of β-hexosaminidase from skin slices in vitro. Life Sci 2006; 78: 598-606.
Hanuš L, Breuer A, Tchilibon S, Shiloah S, Goldenberg D, Horowitz M, Pertwee RG, Ross RA, Mechoulam R, Fride E. HU-308: A specific agonist for CB2, a peripheral cannabinoid receptor. P Natl Acad Sci USA 1999; 96: 14228-14233.
Bueb JL, Lambert DM, Tschirhart EJ. Receptor-independent effects of natural cannabinoids in rat peritoneal mast cells in vitro. BBA-Mol Cell Res 2001; 1538: 252-259.
Vannacci A, Giannini L, Passani MB, Di Felice A, Pierpaoli S, Zagli G, Fantappie O, Mazzanti R, Masini E, Mannaioni PF. The endocannabinoid 2-arachidonylglycerol decreases the immunological activation of guinea pig mast cells: involvement of nitric oxide and eicosanoids. J Pharmacol Exp Ther 2004; 311: 256-264.